Skip to content

Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02648399
Enrollment
300
Registered
2016-01-07
Start date
2015-12-31
Completion date
2016-12-31
Last updated
2016-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Papillary Carcinoma

Keywords

thyroid carcinoma, center lymph node dissection

Brief summary

This study recruit the patients with unilateral papillary thyroid cancer before operation,the patients agree to enter the test,and divided into experimental and control group.experimental group patients receive the surgery including unilateral thyroid lobectomy and bilateral central lymph node dissection.and control group receive the surgery including unilateral thyroid lobectomy and unilateral central lymph node dissection.last the investigators compare numbers of patient with tumor recurrence and metastasis rate of 5 years,numbers of metastatic lymph node,and numbers of participants with adverse events related to treatment between two groups in order to evaluate the significance of bilateral lymph node dissection.

Interventions

PROCEDUREsurgery:BCND(bilateral central lymph node dissection)
PROCEDUREsurgery:UCND(unilateral central lymph node dissection)

Sponsors

Fujian Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
15 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

according by thyroid carcinoma TNM(tumor,lymph node, metastasis) staging of NCCN (National Comprehensive Cancer Network) Inclusion Criteria: * 1.Unilateral thyroid papillary carcinoma 2.TNM staging: T1\ 2N0M0

Exclusion criteria

* 1.Bilateral thyroid papillary carcinoma 2.isthmus thyroid carcinoma 3.TNM staging: T3orT4 4.Clinic N1orM1

Design outcomes

Primary

MeasureTime frameDescription
tumor recurrence5 yearsnumbers of patients with tumor recurrence
numbers of metastatic lymph node1 yearsnumbers of metastatic lymph node
adverse events related to treatment1 yearsnumbers of participants with adverse events including recurrent nerve injury,parathyroid injury,hemorrhage

Secondary

MeasureTime frameDescription
relations between the lymph metastasis and TNM staging1 yearsCoefficient R (SPSS software for correlation analysis)
relations between the lymph metastasis and tumor location1 yearsCoefficient R (SPSS software for correlation analysis)

Countries

China

Contacts

Primary Contactwenxin zhao, doctor
fzhzwx6688@163.com08613365910359
Backup Contactshouyi yan, master
yansy1985@163.com0861598230279

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026